Compare LUNG & INGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LUNG | INGN |
|---|---|---|
| Founded | 1995 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.9M | 172.4M |
| IPO Year | 2020 | 2013 |
| Metric | LUNG | INGN |
|---|---|---|
| Price | $1.27 | $7.05 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | $5.38 | ★ $11.25 |
| AVG Volume (30 Days) | ★ 338.9K | 261.2K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 7.64 | ★ 43.42 |
| EPS | N/A | ★ N/A |
| Revenue | $90,497,000.00 | ★ $348,668,000.00 |
| Revenue This Year | $2.48 | $8.03 |
| Revenue Next Year | $18.46 | $7.76 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 8.01 | 3.86 |
| 52 Week Low | $1.13 | $5.34 |
| 52 Week High | $5.46 | $9.13 |
| Indicator | LUNG | INGN |
|---|---|---|
| Relative Strength Index (RSI) | 40.15 | 62.15 |
| Support Level | $1.13 | $6.59 |
| Resistance Level | $1.64 | $7.63 |
| Average True Range (ATR) | 0.10 | 0.35 |
| MACD | -0.00 | 0.06 |
| Stochastic Oscillator | 10.79 | 75.30 |
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.
Inogen Inc is a medical technology business that focuses on respiratory health. It develops, manufactures, and markets respiratory health products, including portable oxygen concentrators, or POCs, used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions and the Simeox product for airway clearance treatment. In addition, it has started distributing the Inogen Voxi 5 stationary oxygen concentrator as well as the Aurora continuous positive airway pressure, or CPAP, masks in the United States. The company derives revenues from customers through the development, manufacturing, marketing, sales, and rental of respiratory products.